<DOC>
	<DOCNO>NCT01491022</DOCNO>
	<brief_summary>The purpose study evaluate effect AMPYRA number symptom Parkinson 's disease . AMPYRA medication approve FDA gait dysfunction multiple sclerosis . There multiple study suggest person multiple sclerosis benefit medication major improvement gait take medication . However , medication never study Parkinson 's disease . This study aim learn possible benefit AMPYRA Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>A Randomized Trial Evaluate Ampyra Gait Impairment Parkinson 's Disease</brief_title>
	<detailed_description>Subjects Parkinson 's disease randomly assign two group . One group receive Ampyra first 4 week , follow 2 week break 4 week placebo second group first receive placebo Ampyra .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Idiopathic PD stage Hoehn Yahr Stage &gt; 13 gait freeze postural instability . On stable dosage dopamine agonist/levodopa , expect remain dosage treatment duration study Age le 80 , onset disease age 45 . Able give consent Past medical history seizure , History renal insufficiency , History cardiac arrhythmia , Severe arthritis , Women childbearing potential , Cognitive impairment Age 80 . PD patient stage 4 H &amp; Y PD patient recent introduction dopamine agonist IMAO B PD patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>parkinson 's</keyword>
	<keyword>gait dysfunction</keyword>
	<keyword>ampyra</keyword>
	<keyword>4-aminopyridine</keyword>
</DOC>